NAUT vs. AKYA, SEER, BCAB, PACB, ORIC, TALS, AFMD, QTRX, EYPT, and VBIV
Should you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Akoya Biosciences (AKYA), Seer (SEER), BioAtla (BCAB), Pacific Biosciences of California (PACB), ORIC Pharmaceuticals (ORIC), Talaris Therapeutics (TALS), Affimed (AFMD), Quanterix (QTRX), EyePoint Pharmaceuticals (EYPT), and VBI Vaccines (VBIV). These companies are all part of the "medical" sector.
Nautilus Biotechnology (NASDAQ:NAUT) and Akoya Biosciences (NASDAQ:AKYA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.
Akoya Biosciences has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Akoya Biosciences, indicating that it is currently the more affordable of the two stocks.
Nautilus Biotechnology has a net margin of 0.00% compared to Akoya Biosciences' net margin of -72.68%. Nautilus Biotechnology's return on equity of -24.94% beat Akoya Biosciences' return on equity.
Akoya Biosciences received 25 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 60.87% of users gave Akoya Biosciences an outperform vote while only 16.67% of users gave Nautilus Biotechnology an outperform vote.
Nautilus Biotechnology currently has a consensus price target of $6.00, suggesting a potential upside of 104.78%. Akoya Biosciences has a consensus price target of $7.79, suggesting a potential upside of 177.07%. Given Akoya Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Akoya Biosciences is more favorable than Nautilus Biotechnology.
50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 79.4% of Akoya Biosciences shares are owned by institutional investors. 42.5% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 7.3% of Akoya Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Nautilus Biotechnology has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Akoya Biosciences has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
In the previous week, Akoya Biosciences had 15 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 16 mentions for Akoya Biosciences and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 1.87 beat Akoya Biosciences' score of -0.16 indicating that Nautilus Biotechnology is being referred to more favorably in the media.
Summary
Akoya Biosciences beats Nautilus Biotechnology on 11 of the 17 factors compared between the two stocks.
Get Nautilus Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nautilus Biotechnology Competitors List
Related Companies and Tools
